London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
11don MSN
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision ...
A Phase 3 trial found AstraZeneca's experimental lung cancer drug did not significantly improve patients' overall survival rates.
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...
Deutsche Bank downgrades AstraZeneca (AZN) and Roche (RHHBY) after disappointing data for thier key pipeline assets. Read ...
UK stocks are holding firm, with the FTSE 100 up 0.3% and the FTSE 250 by 0.9%. US stocks are now open and aren’t moving much ...
News Medical on MSN7d
New cancer drug shows encouraging results in Phase I/II trialThe antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced ...
--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab ... discovered by Daiichi Sankyo and being jointly developed and commercialized by ...
Relay Therapeutics said on Monday interim data from an early-stage study of its combination drug for breast cancer showed it ...
“It's very natural to put China and the U.S. together” because of the scale of the challenge in both countries, co-founder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback